Liquidia Corporation $LQDA Shares Acquired by AlphaQuest LLC

AlphaQuest LLC boosted its stake in Liquidia Corporation (NASDAQ:LQDA) by 4,240.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,753 shares of the company’s stock after acquiring an additional 17,344 shares during the period. AlphaQuest LLC’s holdings in Liquidia were worth $404,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Tyro Capital Management LLC bought a new position in Liquidia during the 2nd quarter worth approximately $15,473,000. CenterBook Partners LP boosted its holdings in Liquidia by 811.7% in the second quarter. CenterBook Partners LP now owns 1,103,850 shares of the company’s stock worth $13,754,000 after purchasing an additional 982,778 shares during the period. Federated Hermes Inc. bought a new stake in Liquidia during the third quarter valued at $7,290,000. BNP Paribas Financial Markets raised its holdings in shares of Liquidia by 157.2% during the second quarter. BNP Paribas Financial Markets now owns 482,822 shares of the company’s stock worth $6,016,000 after purchasing an additional 295,104 shares during the period. Finally, Marshall Wace LLP lifted its position in shares of Liquidia by 58.6% in the 2nd quarter. Marshall Wace LLP now owns 660,762 shares of the company’s stock worth $8,233,000 after buying an additional 244,235 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $43.04 on Friday. The stock has a market cap of $3.74 billion, a P/E ratio of -29.89, a P/E/G ratio of 1.17 and a beta of 0.46. The firm’s 50-day simple moving average is $36.69 and its 200 day simple moving average is $28.92. Liquidia Corporation has a fifty-two week low of $11.26 and a fifty-two week high of $46.67. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on LQDA shares. HC Wainwright increased their price objective on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Needham & Company LLC boosted their price objective on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Wells Fargo & Company initiated coverage on Liquidia in a research note on Monday, October 20th. They set an “overweight” rating and a $31.00 price objective for the company. Finally, Wall Street Zen lowered shares of Liquidia from a “buy” rating to a “hold” rating in a research report on Sunday, January 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $39.67.

Insider Activity at Liquidia

In other news, CAO Dana Boyle sold 1,580 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $41.65, for a total value of $65,807.00. Following the completion of the sale, the chief accounting officer directly owned 178,848 shares of the company’s stock, valued at approximately $7,449,019.20. This represents a 0.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Michael Kaseta sold 36,932 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,382,364.76. Following the transaction, the chief financial officer owned 350,919 shares in the company, valued at $13,134,898.17. This represents a 9.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 252,476 shares of company stock worth $9,173,435 in the last three months. Insiders own 26.50% of the company’s stock.

Liquidia Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).